P683: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS)

Journal article

Open access

Peer reviewed

HemaSphere, Vol.6, pp.579-580

2022-06-01

Files and links (1)

url

https://doi.org/10.1097/01.hs9.0000845616.77820.49View

Published (Version of record) Open

1 Record Views

Title: P683: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS)
Creators: Alvaro Alencar - Miller School of Medicine
Publication Details: HemaSphere, Vol.6, pp.579-580
Publisher: Wolters Kluwer
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031757821202976